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management). As studies emerge that demonstrate the clinical
utility of a test, the test naturally becomes more widely available
and eventually more affordable.
With respect to testing for mutations for familial dilated
cardiomyopathy (FDC), the authors point out that there are 9
clinical genetic testing laboratories performing sequencing for
lamin A/C. Centers such as these can continue to provide the field
with valuable information on mutation frequency, mutation-
specific natural history, and mutation-specific interventions; such
information is vital to absorbing testing into the clinical commu-
nity at large. We agree that individuals with FDC with access to
such genetic testing laboratories may wish to proceed with genetic
testing after appropriate counseling, as information on family risk
can be useful in those who test positive for the lamin A/C
mutations. As we mentioned in our report, “The natural history of
familial dilated cardiomyopathy is not known with the exception of
some rare cases (lamin A/C), and mutation-specific interventions
beyond standard heart failure therapy and genetic counseling do
not exist” (1). We agree that all individuals with inherited
cardiomyopathies should receive the appropriate genetic counsel-
ing. We did not address the conditions of hypertrophic cardiomy-
opathy or arrhythmogenic right ventricular cardiomyopathy as
these are to be considered in other studies from the series on
cardiovascular genomic medicine.
Again, we applaud the proactive stance of the authors. In this
climate of direct-to-consumer advertising we would prefer that
genetic testing be facilitated through a patient–doctor relationship
and not obtained through one of many emerging commercial
entities.
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Cardiac Mast Cells:
Implications for Heart Failure
Kim et al. (1) reported that in patients with chronic heart failure
(CHF), the H2-histamine receptor antagonist famotidine im-
proved both cardiac symptoms and ventricular remodeling, which
was suggested to be an indirect hint for a role of histamine and its
receptors in the failing heart. More direct conclusions might be
deduced from investigations of patients with systemic mastocytosis
who have an increased myocardial histamine concentration due to
an increased mast cell density in the heart. Here we report findings
observed in 17 patients with systemic mast cell activation disorder
(2) who, among other symptoms, had a mast cell mediator-
induced tachycardia indicating a significant infiltration in the heart
by pathologically activated mast cells. One should expect that,
because of the long time course of the disease (median duration of
illness: 14 years), a contribution of a continuously increased
histamine concentration in the heart should have become observ-
able in those patients. In echocardiography, left ventricular dia-
stolic and systolic diameter, fractional shortening, and ejection
fraction were not pathologically altered in our patients. However,
a diastolic left ventricular dysfunction occurred in 12 of 17 patients
as determined by pulse wave- and/or tissue-Doppler imaging,
which represents a sensitive first sign of a myocardial textural
alteration. In 5 of those 12 patients a left ventricular hypertrophy
was observed. Because of the absence of other precipitating factors,
these alterations are probably due to the remodeling effect of
prohypertrophic cytokines and proteases and profibrotic growth
factors synthesized and secreted by mast cells (3).
In conclusion, our findings do not support the contention that
an increased myocardial histamine concentration alone, even over
a long period, leads to CHF because of a direct effect on the
cardiac myocytes. The beneficial effect of the H2-histamine recep-
tor antagonist famotidine on CHF described by Kim et al. (1) may
rather indicate an indirect role of histamine in the evolution and
progression of CHF. In this context, it is conceivable that
H2-histamine receptor antagonists may reduce the activity of the
mast cells in the heart by blocking H2-histamine receptors on them
and, thereby, may reduce release of those mast cell mediators
which, according to animal experiments and to our aforemen-
tioned findings, can induce a remodeling of the heart with an
associated functional distortion.
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Reply
We appreciated the important comments of Dr. Kolck and
colleagues regarding our study (1) showing that histamine is
involved in pathophysiology in the patients with moderate to
severe chronic heart failure (CHF). They investigated patients
with systemic mastocytosis who have an increased mast cell
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infiltration in the heart and, hence, an increased myocardial
histamine concentration. In such patients, the prevalence of left
ventricular (LV) systolic dysfunction was not increased; however,
diastolic LV dysfunction occurred in 70% of the patients, and 30%
of the patients suffered from LV hypertrophy. They argued that
there is a disparity between their observation and our study
showing that histamine-H2 blockers improve the severity of CHF
pathophysiology (1,2). However, we do not consider that their
observation contradicts ours, but rather it supports our findings.
We showed that histamine is deleterious in the process or
progression of CHF via activation of H2-receptors, but did not
show that histamine is one of the causes of CHF. This is the same
as in the role of catecholamine or angiotensin II in the pathophys-
iology of CHF. Even if catecholamine or angiotensin II is
continuously administered to animal models, infusion of catechol-
amine or angiotensin II only produces LV hypertrophy, but does
not produce severe heart failure (3). In the clinical setting, we have
seen that in patients with pheochromocytoma or angiotensin-
producing tumor, LV hypertrophy is only observed without overt
CHF. These observations are consonant with those of Kolck et al.,
suggesting that catecholamine, angiotensin II, or histamine does
not potentially cause CHF such as virus infection, but decreases
the threshold to CHF in patients with ventricular dysfunction.
It is intriguing that histamine exposures over a long time can
cause LV diastolic dysfunction with LV hypertrophy, suggesting
that histamine is able to cause mild ventricular damages. This
mechanism may worsen the pathophysiology of pre-existing CHF
caused by essential hypertension, myocardial infarction, or cardiac
myocarditis/myopathy. Therefore, we believe that histamine-H2
blocker improves some aspects of the pathophysiology of CHF.
We are working in a model of canine pacing-induced CHF or the
model of pressure overload-induced CHF in histamine-H2 recep-
tor knock-out mice to investigate the potential and novel role of
histamine and histamine receptors in CHF.
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